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Global Initiative for Asthma (GINA)
What’s New in GINA 2021?

GINA Global Strategy for Asthma
Management and Prevention
This slide set is restricted for academic and educational purposes only. No additions
or changes may be made to slides. Use of the slide set or of individual slides for
commercial or promotional purposes requires approval from GINA.

About GINA Recommendations
§

Other considerations in making recommendations
▪

Patient priorities and preferences

▪

Patient behavior, including adherence

▪

Current understanding of underlying disease processes

▪

Feasibility for implementation in clinical practice

© Global Initiative for Asthma, www.ginasthma.org

GINA guidance about
COVID-19 and asthma
Updated 26 April 2021

GINA Global Strategy for Asthma
Management and Prevention
www.ginasthma.org

COVID-19 and Asthma
§

Are people with asthma at increased risk of COVID-19, or severe COVID-19?
▪

§

People with asthma do not appear to be at increased risk of acquiring COVID-19, and systematic reviews have
not shown an increased risk of severe COVID-19 in people with well-controlled, mild-to-moderate asthma

Are people with asthma at increased risk of COVID-19-related death?
▪

Overall, people with well-controlled asthma are not at increased risk of COVID-19-related death
(Williamson, Nature 2020; Liu et al JACI IP 2021)

▪

However, the risk of COVID-19 death was increased in people who had recently needed oral corticosteroids
(OCS) for their asthma (Williamson, Nature 2020) and in hospitalized patients with severe asthma (Bloom, Lancet
Respir Med 2021).

Updated 26 April 2021

© Global Initiative for Asthma, www.ginasthma.org

COVID-19 and Asthma - Medications
Advise patients to continue taking their prescribed asthma medications, particularly inhaled
corticosteroids (ICS)
▪

For patients with severe asthma, continue biologic therapy or oral corticosteroids if prescribed

Are ICS protective in COVID-19?
▪

In one study of hospitalized patients aged ≥50 years with COVID-19, ICS use in those with asthma was
associated with lower mortality than in patients without an underlying respiratory condition (Bloom, Lancet RM 2021)

Make sure that all patients have a written asthma action plan, advising them to:
▪

Increase controller and reliever medication when asthma worsens (see GINA report Box 4-2)

▪

Take a short course of OCS when appropriate for severe asthma exacerbations

Avoid nebulizers where possible, to reduce the risk of spreading virus
▪

Pressurized metered dose inhaler via a spacer is preferred except for life-threatening exacerbations

▪

Add a mouthpiece or mask to the spacer if required

Updated 26 April 2021

© Global Initiative for Asthma, www.ginasthma.org

A reminder – A Key Change in Asthma Management

Reddel et al, ERJ 2019; 53: 1901046

© Global Initiative for Asthma, www.ginasthma.org

GINA 2019 – Landmark Changes in Asthma Management
§

Recommends against SABA-only treatment for Step 1 in adults and adolescents
▪

§

SABA-only treatment increases the risk of severe exacerbations, and that adding any ICS
significantly reduces the risk

All adults and adolescents with asthma should receive ICS-containing controller
treatment, to reduce the risk of serious exacerbations
▪

The ICS can be delivered by regular daily treatment or, in mild asthma, by as-needed low dose
ICS-formoterol

ICS: inhaled corticosteroids; SABA: short-acting beta2-agonist
© Global Initiative for Asthma, www.ginasthma.org

Background - The Risks of ‘Mild’ Asthma
§

§

Patients with apparently mild asthma are still at risk of serious adverse events
▪
▪

30–37% of adults with acute asthma
16% of patients with near-fatal asthma

▪

15–20% of adults dying of asthma

had symptoms less than weekly in previous
3 months (Dusser, Allergy 2007)

Exacerbation triggers are unpredictable (viruses, pollens, pollution, poor adherence)

SABA: short-acting beta2-agonist
© Global Initiative for Asthma, www.ginasthma.org

Background - The Risks of SABA-Only Treatment
§

Regular use of SABA, even for 1–2 weeks, is associated with adverse effects
▪

b -receptor downregulation, decreased bronchoprotection, rebound hyperresponsiveness,
decreased bronchodilator response

§

Higher use of SABA is associated with adverse clinical outcomes

§

Inhaled corticosteroids reduce the risk of asthma deaths, hospitalization and exacerbations
requiring oral corticosteroids (OCS)
▪

§

BUT adherence is poor, particularly in patients with mild or infrequent symptoms

A safe and effective alternative was needed for mild asthma

OCS: oral corticosteroids; SABA: short-acting beta2-agonist
© Global Initiative for Asthma, www.ginasthma.org

Original Article

As-Needed Budesonide–Formoterol versus
Maintenance Budesonide in Mild Asthma
Eric D. Bateman, M.D., Helen K. Reddel, M.B., B.S., Ph.D., Paul M. O’Byrne, M.B.,
Peter J. Barnes, M.D., Nanshan Zhong, Ph.D., Christina Keen, M.D., Carin
Jorup, M.D., Rosa Lamarca, Ph.D., Agnieszka Siwek-Posluszna, M.D., and J. Mark
FitzGerald, M.D.

N Engl J Med
Volume 378(20):1877-1887
May 17, 2018

Study Overview
• Inhaled glucocorticoid plus β-agonist in a single inhaler was compared
with maintenance inhaled glucocorticoid for exacerbation risk among
patients with mild asthma.
• Combination therapy was noninferior to maintenance therapy.

Annualized Rate of Severe Asthma Exacerbations and Time to First Severe Exacerbation.

Bateman ED et al. N Engl J Med 2018;378:1877-1887

O’Byrne PM et al. N Engl J Med 2018;378:1865-1876

O’Byrne PM et al. N Engl J Med 2018;378:1865-1876

The GINA 2021 Treatment Figure for Adults and Adolescents
§

Track 1, with low dose ICS-formoterol as the reliever, is the preferred approach
▪

§

Using ICS-formoterol as reliever reduces the risk of exacerbations compared with using
a SABA reliever, with similar symptom control and similar lung function

Track 2, with SABA as the reliever, is an alternative approach
▪

Use this if Track 1 is not possible, or is not preferred by a patient with no exacerbations on their
current controller therapy

▪

Before considering a regimen with SABA reliever, consider whether the patient is likely to be
adherent with daily controller – if not, they will be exposed to the risks of SABA-only treatment

ICS: inhaled corticosteroids; SABA: short-acting beta2-agonist
© Global Initiative for Asthma, www.ginasthma.org

Confirmation of diagnosis if necessary
Symptom control & modifiable
risk factors (including lung function)
Comorbidities
Inhaler technique & adherence
Patient preferences and goals

Adults & adolescents
12+ years
Personalized asthma management
Assess, Adjust, Review
for individual patient needs

Symptoms
Exacerbations
Side-effects Lung
function Patient
satisfaction

Treatment of modifiable risk factors
and comorbidities
Non-pharmacological strategies
Asthma medications (adjust down/up/between tracks)
Education & skills training

STEP 5

CONTROLLER and
PREFERRED RELIEVER
(Track 1). Using ICS-formoterol
as reliever reduces the risk of
exacerbations compared with
using a SABA reliever

CONTROLLER and
ALTERNATIVE RELIEVER
(Track 2). Before considering a
regimen with SABA reliever,
check if the patient is likely to be
adherent with daily controller
Other controller options
for either track

GINA 2021, Box 3-5A

STEP 3

STEPS 1 – 2

Low dose
maintenance
ICS-formoterol

As-needed low dose ICS-formoterol

STEP 4
Medium dose
maintenance
ICS-formoterol

Add-on LAMA
Refer for phenotypic
assessment ± anti-IgE,
anti-IL5/5R, anti-IL4R
Consider high dose
ICS-formoterol

RELIEVER: As-needed low-dose ICS-formoterol

STEP 1
Take ICS whenever
SABA taken

STEP 3

STEP 2
Low dose
maintenance ICS

Low dose
maintenance
ICS-LABA

STEP 4
Medium/high dose
maintenance ICSLABA

STEP 5
Add-on LAMA
Refer for phenotypic
assessment ± anti-IgE,
anti-IL5/5R, anti-IL4R
Consider high dose
ICS-LABA

RELIEVER: As-needed short-acting β2-agonist
Low dose ICS whenever
SABA taken, or daily LTRA,
or add HDM SLIT

Medium dose ICS, or
add LTRA, or add
HDM SLIT

Add LAMA or LTRA or
HDM SLIT, or switch to
high dose ICS

Add azithromycin (adults) or
LTRA; add low dose OCS
but consider side-effects

© Global Initiative for Asthma, www.ginasthma.org

GINA Track 1 (preferred): The Reliever is Low Dose ICS-Formoterol
§

Why is this preferred for adults and adolescents?
▪

§

§

Because using low dose ICS-formoterol as reliever reduces the risk of severe exacerbations
compared with regimens with SABA as reliever, with similar symptom control

How is it used?
▪

When a patient at any treatment step has asthma symptoms, they use low dose ICS-formoterol
in a single inhaler for symptom relief

▪

In Steps 3–5, patients also take ICS-formoterol as their daily controller treatment. Together, this
is called ‘maintenance and reliever therapy’ or ‘MART’

When should it not be used?
▪

ICS-formoterol should not be used as the reliever in patients prescribed a different ICS-LABA for
their controller therapy

ICS: inhaled corticosteroids; SABA: short-acting beta2-agonist
© Global Initiative for Asthma, www.ginasthma.org

GINA Track 2 (Alternative): The Reliever is SABA
§

When should this be used?
▪

§

This is an alternative approach for adults and adolescents if Track 1 is not possible, or is not
preferred by a patient with no exacerbations on their current therapy

When should it not be used?
▪

Before prescribing a regimen with SABA reliever, consider whether the patient is likely to be
adherent with their prescribed ICS-containing controller therapy. If they are poorly adherent, they
will be at higher risk of exacerbations

ICS: inhaled corticosteroids; SABA: short-acting beta2-agonist
© Global Initiative for Asthma, www.ginasthma.org

Subepithelial Layer Thickness (µm)

Airway Remodeling is Airway Scarring:
An Issue Even in Mild Asthma
30

P<0.003
P<0.01

25
20

# P < 0.001, healthy vs.
patients with asthma

15
10
5

#

0
Severe
(n=6)

Moderate
(n=14)

Mild
(n=14)

Healthy Subjects
(n=8)

Mean and individual values of subepithelial layer thickness in patients with
severe, moderate, and mild asthma, and healthy subjects
Chetta et al. CHEST. 1997; 111:852-857.

A 23-year-old woman with intermittent
asthma managed with PRN inhaler use
only presents with an acute asthma flare
brought on by a URI. She improves but is
not totally clear after two neb treatments.
The most appropriate discharge treatment
plan is:
A.
B.
C.
D.

Continue PRN inhaler use but
follow-up if symptoms recur.
Use the inhaler until the URI
resolves.
Use the inhaler BID and “as
needed”.
Prescribe a 5- day steroid burst
and continue the inhaler both
BOD and “as needed”.

Steroids or No Steroids
for Acute Exacerbation
§ Systematic review of six trials (374
participants)
§ RR = 0.38 relapse within one week
§ RR = 0.35 subsequent hospitalization (21
days)
Cochrane Rev 2007

More on Steroids
§ Early (within one hour) benefit
§ Systematic review of 12 studies (863
participants)
§ OR of hospitalization = 0.40
Cochrane 2001

STARTING TREATMENT
in adults and adolescents with a diagnosis of asthma
Track 1 is preferred if the patient is likely to be poorly adherent with daily controller
ICS-containing therapy is recommended even if symptoms are infrequent, as it
reduces the risk of severe exacerbations and need for OCS.

FIRST
ASSESS:

• Confirm diagnosis
• Symptom control
and modifiable risk
factors, including
lung function

START
HERE IF:

CONTROLLER and
PREFERRED RELIEVER
(Track 1). Using ICS-formoterol
as reliever reduces the risk of
exacerbations compared with
using a SABA reliever

Symptoms most
days, or waking
with asthma once
a week or more

Symptoms less
than 4–5 days
a week

Low dose
maintenance
ICS-formoterol

As-needed low dose ICS-formoterol

Short course OCS
may also be needed
for patients presenting
with severely
uncontrolled asthma

STEP 5
STEP 4

STEP 3

STEPS 1 – 2

Daily symptoms,
or waking with
asthma once a
week or more,
and low lung
function

Medium dose
maintenance
ICS-formoterol

Add-on LAMA Refer
for phenotypic
assessment ± anti-IgE,
anti-IL5/5R, anti-IL4R
Consider high dose
ICS-formoterol

RELIEVER: As-needed low-dose ICS-formoterol

• Comorbidities
• Inhaler technique
and adherence
• Patient preferences
and goals

START
HERE IF:

CONTROLLER and
ALTERNATIVE RELIEVER
(Track 2). Before considering
a regimen with SABA reliever,
check if the patient is likely
to be adherent with daily
controller therapy

GINA 2021, Box 3-4Bi

Symptoms less
than twice a
month

STEP 1
Take ICS whenever
SABA taken

Symptoms twice
a month or more,
but less than 4–5
days a week

Symptoms most
days, or waking
with asthma once
a week or more

STEP 3

STEP 2
Low dose
maintenance ICS

Low dose
maintenance
ICS-LABA

Daily symptoms,
or waking with
asthma once a
week or more,
and low lung
function

STEP 4
Medium/high
dose maintenance
ICS-LABA

Short course OCS
may also be needed
for patients presenting
with severely
uncontrolled asthma

STEP 5
Add-on LAMA Refer
for phenotypic
assessment ± anti-IgE,
anti-IL5/5R, anti-IL4R
Consider high dose
ICS-LABA

RELIEVER: As-needed short-acting β2-agonist

© Global Initiative for Asthma, www.ginasthma.org

STARTING TREATMENT
in adults and adolescents 12+ years with a diagnosis of asthma
FIRST ASSESS:

IF:

START WITH:

Confirmation
of diagnosis

Daily symptoms, waking at
night once a week or more
and low lung function?

TRACK 1
(preferred)

OR

TRACK 2

YES

Medium dose
ICS-formoterol
maintenance and
reliever (MART)

Medium/high
dose ICS-LABA
+ as-needed SABA

STEP 4

YES

Low dose
ICS-formoterol
maintenance and
reliever (MART)

Low dose
ICS-LABA
+ as-needed SABA

STEP 3

YES

As-needed low dose
ICS-formoterol

Low dose ICS
+ as-needed SABA

STEP 2

Short course OCS may
also be needed for patients
presenting with severely
uncontrolled asthma

NO

Symptom control
& modifiable risk
factors (including
lung function)

Comorbidities

Inhaler technique
& adherence

Symptoms most days,
or waking at night once
a week or more?

NO

Symptoms twice a
month or more?

NO

Patient preferences
& goals

GINA 2021, Box 3-4Bii

As-needed low dose
ICS-formoterol

Take low dose
ICS whenever
SABA is taken

STEP 1

As-needed ICS-formoterol
is preferred if the patient is
likely to be poorly adherent
with daily ICS
ICS-containing therapy
is recommended even if
symptoms are infrequent,
as it reduces the risk of
severe exacerbations and
need for OCS.

© Global Initiative for Asthma, www.ginasthma.org

Maintenance and Reliever Therapy (MART) in Steps 3–5
§

M aintenance and reliever therapy (MART) with ICS-formoterol reliever reduces the
risk of severe exacerbations compared with regimens with SABA reliever
▪

Compared with same dose or higher dose ICS-LABA, in patients with history of severe
exacerbations (Sobieraj, JAMA 2018)

▪

Compared with conventional best practice, in broad populations (Cates, Cochrane 2013, Demoly
Respir Med 2009)

§

M aintenance and reliever therapy (MART) in Step 4
▪

§

ICS responsiveness varies, and some patients whose asthma is uncontrolled on MART with low
dose ICS-formoterol despite good adherence and correct inhaler technique may benefit from
increasing the total daily maintenance dose to medium

M aintenance and reliever therapy (MART) in Step 5
▪

There is no direct evidence about initiating MART in patients receiving add-on treatment such as
LAMA or biologic therapy, but if a patient is already taking MART, switching them to conventional
ICS-LABA plus as-needed SABA may increase the risk of exacerbations
ICS: inhaled corticosteroids; LABA: long-acting beta2-agonist; OCS: oral corticosteroids; SABA: short-acting beta2-agonist
© Global Initiative for Asthma, www.ginasthma.org

Add-On Long-Acting Muscarinic Antagonists (LAMA)
§

Step 5 recommendations for add-on LAMA have been expanded to include combination
ICS-LABA-LAMA, if asthma is persistently uncontrolled despite ICS-LABA
▪
▪

Add-on tiotropium in separate inhaler (ages ≥6 years)
Triple combinations (ages ≥ 18 years): beclometasone-formoterol-glycopyrronium; fluticasone
furoate-vilanterol-umeclidinium; mometasone-indacaterol-glycopyrronium

ICS: inhaled corticosteroids; LABA: long-acting beta2-agonist; LAMA: long-acting muscarinic antagonist; OCS: oral corticosteroids
© Global Initiative for Asthma, www.ginasthma.org

Add-On Azithromycin
§

Add-on azithromycin three days a week has been confirmed as an option for
consideration after specialist referral
▪

Significantly reduces exacerbations in patients taking high dose ICS-LABA

▪

Significantly reduces exacerbations in patients with eosinophilic or non-eosinophilic asthma

▪

No specific evidence published for azithromycin in patients taking medium dose ICS-LABA
(Hiles et al, ERJ 2019)

§

Before considering add-on azithromycin
▪

Check sputum for atypical mycobacteria

▪
▪

Check ECG for long QTc (and re-check after a month of treatment)
Consider the risk of increasing antimicrobial resistance (population or personal)

ICS: inhaled corticosteroids; LABA: long-acting beta2-agonist
© Global Initiative for Asthma, www.ginasthma.org

Add-On Biologic Therapy for Severe Type 2 Asthma
§

When assessing eligibility, repeat blood eosinophils if low at first assessment
▪

§

§

One study found that 65% patients on medium or high dose ICS-LABA shifted their eosinophil
category during 12 months’ follow-up (Lugogo et al, Ann Allergy Asthma Immunol 2020)

Additional indications for these therapies in Europe and/or USA have been listed
▪

Omalizumab: chronic idiopathic urticaria, nasal polyposis

▪

Mepolizumab: hypereosinophilic syndrome, eosinophilic granulomatosis with polyangiitis (EGPA)

▪

Benralizumab: no additional indications at present

▪

Dupilumab: chronic rhinosinusitis with nasal polyposis (CRSwNP); atopic dermatitis

Check local regulatory approvals and eligibility criteria

ICS: inhaled corticosteroids; LABA: long-acting beta2-agonist
© Global Initiative for Asthma, www.ginasthma.org

A 30 year old man with moderate persistent asthma
is in the ED with an acute exacerbation. After 3 nebs
(albuterol plus ipratropium) and a loading dose of 60
mg prednisone his PEFR has improved from 180 to
260 l/min (PEF predicted=600 l/min).
Of the following, the most appropriate step is:
A.
B.
C.
D.

Discharge to home.
Add montelukast PO.
Give an IV loading dose of theophylline.
Give IV magnesium.

A 45 year old former smoker is currently being treated with
an ICS/LABA and an LTRA. He reports that he still requires
his rescue inhaler 3 or 4 times a day.

An appropriate next step would be:
A.
B.
C.
D.

Add ipratropium.
Add tiotropium.
Add theophylline.
Add cromolyn.

Tiotropium (Spiriva)
§ Approved by the FDA for
long-term maintenance in asthma
§ 2 inhalations of 1.25 mcg per day.
Ann Am Thor Soc (2016) 13:173

LAMAs in Severe Asthma
§ Adding LAMA vs. placebo to ICS/LABA
Systematic review of 4 trials (1197 parts.)
OR (for exacerbation) = 0.76 (CI, 0.57 – 1.02)
Cochrane 2016
BUT…
§ Systematic review 15 trials (7122 parts.)
LAMA + ICS
RR hosp = 0.67 (0.48 – 0.92)
LAMA + ICS/LABA
RR hosp = 0.87 (0.53 – 1.42)
JAMA (2018) 319:1473

Asthma/COPD Overlap Syndrome
(ACOS)
§ Persistent airflow limitation, partially
reversible
§ Typically 40+ years old with smoking hx
§ Need clinical suspicion, PFTs

GINA 2021: Treatment of Asthma
in Children

GINA Global Strategy for Asthma
Management and Prevention

Children 6-11 years

Confirmation of diagnosis if necessary
Symptom control & modifiable
risk factors (including lung function)
Comorbidities
Inhaler technique & adherence
Child and parent preferences and goals

Personalized asthma management:
Assess, Adjust, Review
Symptoms
Exacerbations
Side-effects
Lung function

Treatment of modifiable risk factors
& comorbidities
Non-pharmacological strategies
Asthma medications (adjust down or up)
Education & skills training

Child and parent
satisfaction

Asthma medication options:
Adjust treatment up and down for
individual child’s needs
PREFERRED
CONTROLLER
to prevent exacerbations
and control symptoms

Other controller
options

RELIEVER

STEP 4
STEP 3
STEP 2

STEP 1

Daily low dose inhaled corticosteroid (ICS)

Low dose ICS
taken whenever
SABA taken

(see table of ICS dose ranges for children)

Consider daily
low dose ICS

Daily leukotriene receptor antagonist (LTRA), or
low dose ICS taken whenever SABA taken

Low dose ICSLABA, OR medium
dose ICS, OR very
low dose* ICSformoterol
maintenance and
reliever (MART)
Low dose
ICS + LTRA

Medium dose
ICS-LABA,
OR low dose†
ICS-formoterol
maintenance
and reliever
therapy (MART).

STEP 5
Refer for
phenotypic
assessment
± higher dose
ICS-LABA or
add-on therapy,
e.g. anti-IgE

Refer for expert
advice
Add tiotropium
or add LTRA

Add-on anti-IL5,
or add-on low
dose OCS,
but consider
side-effects

As-needed short-acting beta2-agonist (or ICS-formoterol reliever for MART as above)
*Very low dose: BUD-FORM 100/6 mcg
†Low dose: BUD-FORM 200/6 mcg (metered doses).

GINA 2021, Box 3-5B
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STARTING TREATMENT
Children 6–11 years with a diagnosis of asthma

ASSESS:

START
HERE IF:

Confirmation of diagnosis
Symptom control & modifiable risk factors
(including lung function)

Comorbidities
Inhaler technique & adherence
Child and parent preferences and goals

Symptoms
twice a month or
more, but less
than daily

Symptoms
less than twice
a month

Symptoms
most days, or
waking with
asthma once a
week or more

STEP 4

Low dose ICSLABA, OR medium
dose ICS, OR very
low dose* ICSformoterol
maintenance and
reliever (MART)

Medium dose
ICS-LABA,
OR low dose†
ICS-formoterol
maintenance
and reliever
therapy (MART).
Refer for expert
advice

Low dose
ICS + LTRA

Add tiotropium
or add LTRA

STEP 3
PREFERRED
CONTROLLER
to prevent exacerbations
and control symptoms

Other controller
options

RELIEVER

STEP 2
STEP 1

Daily low dose inhaled corticosteroid (ICS)

Low dose ICS
taken whenever
SABA taken

(see table of ICS dose ranges for children)

Consider daily
low dose ICS

Daily leukotriene receptor antagonist (LTRA), or
low dose ICS taken whenever SABA taken

Symptoms most
days, or waking
with asthma
once a week or
more, and low
lung function

Short course OCS
may also be needed
for patients presenting
with severely
uncontrolled asthma

STEP 5
Refer for
phenotypic
assessment
± higher dose
ICS-LABA or
add-on therapy,
e.g. anti-IgE

Add-on anti-IL5,
or add-on low
dose OCS,
but consider
side-effects

As-needed short-acting beta2-agonist (or ICS-formoterol reliever for MART as above)
*Very low dose: BUD-FORM 100/6 mcg
†Low dose: BUD-FORM 200/6 mcg (metered doses).

GINA 2021, Box 3-4Di

© Global Initiative for Asthma, www.ginasthma.org

